

Mechanism of lung inflammation associated with inflammatory bowel disease

Sean W Mateer

The University of Newcastle, School of Biomedical Science and Pharmacy

Thesis submitted in the fulfilment of the requirements for the award of Doctor of Philosophy.

Sean Mateer
4-4-2017

Acknowledgements

As with all endeavours of this nature they cannot be achieved in isolation, therefore I have many people I need to thank for their help during my studies.

I would particularly like to thank my primary supervisor Dr. Simon Keely, who gave me the opportunity to come over to Australia and work in his lab. I am grateful for this opportunity and thankful for all the support and advice I have received during this time. I would also like to thank my co-supervisors Dr. Jay Horvat and Prof. Philip Hansbro; their knowledge during my studies has been invaluable.

Thank you to my colleagues in the gastrointestinal research group for their support in the lab and for being all round good people. I would like to express my thanks to lab members from collaborating research groups, in particular Dr. Steven Maltby, Dr. Hock Tay, Dr. Max Plank and Dr. Andrew Jarnicki.

A special thanks to family, who are always there regardless of how far away. I would also like to thank all the friends I have made during my studies in Newcastle. I wish I could think of something more insightful and philosophical to say but alas I cannot. I would just like to express my deep appreciation to all the staff and students at The University of Newcastle.

Table of contents

Abstract: 6

List of figures 7

List of tables 12

Abbreviations: 13

Chapter 1: Inflammatory bowel disease 19

1.1	Background.....	19
1.2	IBD epidemiology and economic impact	20
1.3	Extra-intestinal manifestations of IBD	23
1.4	Respiratory pathologies associated with IBD.....	23
1.4.1	Subclinical respiratory pathologies	24
1.4.2	Active respiratory disease	26
1.5	Pathogenesis of IBD	27
1.5.1	Gastrointestinal pathophysiology	27
1.5.2	The genetics of IBD	28
1.5.3	Autophagy in IBD pathogenesis	30
1.5.4	Immune-microbiota homeostasis in IBD	30
1.5.5	Soluble mediators of inflammation	32
1.5.6	Intestinal barrier function in IBD	35
1.5.7	Immune responses in the gut	36
1.5.8	Immune responses in IBD	38
1.6	Systemic inflammation associated with IBD.....	39
1.7	Pathophysiology of IBD-induced respiratory disease	40
1.7.1	Immunopathology of IBD-induced respiratory disease	42
1.7.2	Potential mechanisms of IBD-induced respiratory disease	42
1.8	Murine models of IBD.....	44
1.8.1	Dextran sulfate sodium (DSS) colitis	44
1.8.2	2, 4, 6-trinitrobenzenesulfonic acid (TNBS) colitis	44
1.8.3	<i>Winnie</i> colitis	45
1.9	Study aim.....	45

Chapter 2: Methods 47

2.1	Ethics statement.....	47
2.2	DSS murine model of colitis.....	47
2.3	TNBS murine model of colitis.....	48
2.4	<i>Winnie</i> spontaneous colitis	48
2.5	Colon histopathology.....	48

2.6	Pulmonary histopathology and alveolar enlargement.....	51
2.7	Immunohistochemistry for platelet activating factor receptor (PAFR).....	52
2.8	Lung function measurements.....	53
2.9	Airway inflammation, BAL fluid (BAL) collection.....	54
2.10	Differential leucocyte count BAL fluid.....	54
2.11	Cellular analysis of Lungs, blood and bone marrow	54
2.12	Bone marrow colony forming units (CFU) assay.....	57
2.13	Gene expression analysis.....	57
2.14	Cytokine analysis.....	59
2.15	Western blot analysis.....	59
2.16	Reagents and buffers.....	60
2.17	Statistics.....	61
Chapter 3: The effect of intestinal inflammation on the pulmonary system in murine models of colitis 62		
3.1	Introduction.....	62
3.1.1	Hypothesis	62
3.1.2	Aims	63
3.2	Methods	63
3.2.1	Characterisation of respiratory pathologies in murine models of colitis.	63
3.3	Results	64
3.3.1	Intestinal pathology in DSS colitis	64
3.3.2	Physiological effects of colitis on the respiratory system.	70
3.3.3	Immunological effects of colitis on the pulmonary system	76
3.3.4	Gene expression profile in the lungs of DSS colitis mice	81
3.3.5	Mediators of inflammation in DSS colitis-induced pulmonary inflammation	85
3.3.7	Myeloid cell production in DSS colitis	93
3.3.8	Colitis-induced pulmonary pathology in the TNBS model of colitis.	96
3.3.9	Colitis-induced pulmonary pathology in the <i>Winnie</i> model of colitis.	100
3.4	Discussion:.....	103
3.5	Conclusion	106
Chapter 4: The role of systemic IL-6 in the modulation of colitis-induced pulmonary inflammation. 107		
4.1	Introduction.....	107
4.1.1	Hypothesis	109
4.1.2	Aims	109
4.2	Methods	110
4.2.1	Anti-IL-6 intervention in acute DSS colitis	110
4.3	Results	112
4.3.1	Serum IL-6 levels in anti-IL-6 treated acute DSS colitis.	112
4.3.2	Intestinal pathology in anti-IL-6 treated acute DSS colitis.	114
4.3.3:	The influence of IL-6 on colitis-induced pulmonary pathology.	121
4.3.4:	The influence of IL-6 on colitis-induced pulmonary inflammation	125

4.3.5:	Gene expression profile in the lung of anti-IL-6 treated acute DSS colitis.	128
4.3.6	Cytokine and PAFR protein levels in the lung of anti-IL-6 treated acute DSS colitis.	132
4.3.7	Systemic inflammation in anti-IL-6 treated acute DSS colitis.	137
4.3.8	The effect of IL-6 on myeloid cell production in the bone marrow	140
4.4	Discussion.....	142
4.5	Conclusion.....	147
Chapter 5:	Platelet activating factor receptor (PAFR) signalling in the colitis-induced pulmonary inflammation.	148
5.1:	Introduction.....	148
5.1.1	Hypothesis	149
5.1.2	Aims	149
5.2	Methods	150
5.2.1	PAFR antagonist intervention in acute DSS colitis	150
5.3	Results	152
5.3.1	Intestinal pathology in CV-6209 treated acute DSS colitis.	152
5.3.2:	The influence of PAFR antagonism on colitis-induced pulmonary pathology.	160
5.3.3:	The role of PAFR signalling in colitis-induced pulmonary inflammation.	164
5.3.4:	Gene expression profile in the lung of CV-6209 treated acute DSS colitis.	168
5.3.5:	IL-1 β and CCL2 levels in the lung of CV-6209 treated acute DSS colitis.	170
5.3.6:	Systemic inflammation in CV-6209 treated acute DSS colitis.	172
5.4	Discussion.....	176
5.5	Conclusions	182
Chapter 6:	The role of PAFR signalling in the modulation of myeloid cells in colitis-induced pulmonary inflammation.	183
6.1	Introduction.....	183
6.1.1	Hypothesis:	184
6.1.2	Aims	184
6.2	Methods	185
6.2.1	Cell culture	185
6.2.2	DSS serum induced macrophage activation via PAFR signalling	185
6.2.3	CCL2 and LPS macrophage activation via PAFR signalling	186
6.2.4	PAF analysis	186
6.2.5	Bone Marrow neutrophil isolation	186
6.2.6	Assessment of Neutrophil activation via PAFR signalling from products of CCL2 and LPS activated macrophages.	187
6.2.7	Fluorescent <i>in situ</i> hybridisation analysis by flow cytometry (FISH-Flow)	188
6.2.8	Endotoxin assay	189
6.3	Results	190
6.3.1	PAFR expression in the lung of acute DSS colitis mice.	190

Error! Bookmark not defined.

6.3.2	Immunomodulatory factors in the serum of acute DSS colitis mice initiate inflammatory gene expression in macrophages via PAFR signalling. Error! Bookmark not defined.	
6.3.3	Bacterial load is increased in the lungs of acute DSS colitis mice	197
6.3.4	LPS-induced macrophage activation via PAFR signalling.	200
6.3.5	CCL2-induced macrophage activation via PAFR signalling.	204
6.3.6	PAF secretion from CCL2 treated macrophage.	208
6.3.7	The ability of CCL2 activated macrophages to induce the activation of neutrophils via PAFR signalling.	210
6.4	Discussion:.....	214
6.5	Conclusions	218
Chapter 7:	Final discussions	220
7.1	Study findings	220
7.1.1	Respiratory pathologies in murine models of colitis	220
7.1.2	IL-6 mediates systemic inflammation associated with colitis.	222
7.1.3	Cytokine signalling in colitis-induced pulmonary inflammation.	223
7.1.4	The role of PAFR signalling in the initiation of colitis-induced pulmonary inflammation.	225
7.2	Future directions:.....	227
7.3	Study limitations.....	227
7.4	Concluding remarks.....	229
8.0	Appendices	231
9.0	References	277

Abstract:

Inflammatory bowel disease (IBD) is associated with a number of immune-mediated pathologies in peripheral tissues termed extra-intestinal manifestations (EIM). The organs affected by EIM include the lung, liver, skin and eyes. IBD-induced respiratory pathologies are amongst the most prevalent comorbidities associated with IBD. Approximately 54% of IBD patients have some form of respiratory pathology. The respiratory pathologies associated with IBD range from subclinical respiratory inflammation to active respiratory disease. Bronchiectasis and chronic bronchitis are the most common respiratory diseases associated with IBD. The mechanism by which IBD can induce respiratory pathologies is unknown, this knowledge gap is partially due to a lack of basic science research in this field. Thus, the aim of this study was to utilize murine models of colitis to investigate the immunological mechanisms by which IBD can induce respiratory inflammation. In this study it was found that the DSS, TNBS and *Winnie* models of colitis develop pulmonary inflammation that is associated with leucocyte infiltration surrounding the pulmonary vasculature. Pulmonary inflammation in DSS colitis is characterised by neutrophil and monocyte recruitment to the lung. Systemic IL-6 levels were elevated in the DSS colitis model and IL-6 was identified to be a factor that contributes to neutrophil recruitment. It was found that systemic IL-6 mediates neutrophil development in the bone marrow thereby providing the cells required to perpetuate inflammation in the lung. Platelet activating factor receptor (PAFR), IL-1 β and CCL2 expression were increased in the lungs of DSS colitis mice. PAFR signalling in the lung induces the expression of IL-1 β and the recruitment of neutrophils, PAFR signalling did not induce CCL2 expression. It was found that immunomodulatory factors in the serum of DSS colitis induce IL-1 β production and CCL2 gene expression in alveolar macrophage through PAFR signalling. The results from this study identify a number of potential

pathogenic factors that may be involved in the development of IBD-induced respiratory pathologies.

List of figures

Chapter 1

Figure 1.2: Incidence and prevalence of IBD in the time interval 1980 – 2008

Figure 1.5.1: Factors that contribute the pathogenesis of IBD

Figure 1.5.7: T helper subsets, their differentiation factors and secreted cytokines

Figure 1.7: Pictorial illustration of the vicious cycle mode of bronchiectasis and chronic bronchitis pathogenesis.

Chapter 3

Figure 3.3.1A: Weight loss and colon shortening in acute DSS colitis.

Figure 3.3.1B: Histopathological scores in colon sections from acute DSS colitis.

Figure 3.3.1C: Colonic histopathology in acute DSS.

Figure 3.3.1.1A: Cytokine signalling in the colon of acute DSS colitis.

Figure 3.3.2A: Histopathological scores in lung sections from acute DSS colitis.

Figure 3.3.2B: Lung histopathology in acute DSS colitis.

Figure 3.3.2C: Physiological effects of acute DSS colitis on the pulmonary system.

Figure 3.3.2D: PAS-AB staining in lung sections from acute DSS colitis.

Figure 3.3.3A: Leucocyte phenotype in DSS colitis-induced pulmonary inflammation.

Figure 3.3.3B: Airway inflammation in acute DSS colitis.

Figure 3.3.4A: Gene expression profile in the lungs of DSS colitis.

Figure 3.3.4B: Gene expression profile in the lungs of DSS colitis continued.

Figure 3.3.5A: IL-1 β and CCL2 protein levels in the lungs of DSS acute colitis.

Figure 3.3.5B: PAFR protein level in the lungs of acute DSS colitis.

Figure 3.3.6A: Systemic inflammation in acute DSS colitis.

Figure 3.3.6B: Inflammatory cytokines in the circulatory system of acute DSS colitis.

Figure 3.3.7A: Myeloid progenitor cells in the bone marrow of acute DSS colitis.

Figure 3.3.7B: Mature myeloid cell populations in the bone marrow of acute DSS colitis.

Figure 3.3.8A: Histopathological scores in lung sections from TNBS colitis.

Figure 3.3.8B: Histopathology in lung sections from TNBS colitis.

Figure 3.3.8C: Pulmonary inflammation in TNBS colitis.

Figure 3.3.9A: Histopathological scores in lung sections from *Winnie* colitis.

Figure 3.3.8B: Pulmonary pathology in *Winnie* colitis continued

Chapter 4

Figure 4.2.1: Time course of anti-IL-6 interventions in DSS colitis.

Figure 4.3.1A: Weight loss and colon shortening in anti-IL-6 treated DSS colitis.

Figure 4.3.1B: Histopathological scores from colon sections in anti-IL-6 treated DSS colitis.

Figure 4.3.1C: Histopathology in colon sections from control and naïve DSS colitis

Figure 4.3.1D: Histopathology in colon sections from isotype and anti-IL-6 treated DSS colitis.

Figure 4.3.1E: Cytokine signalling in the colon of anti-IL-6 treated acute DSS colitis.

Figure 4.3.2: Histopathological scores in lung sections from anti-IL-6 treated DSS colitis.

Figure 4.3.2B: Histopathology in lung sections from control and naïve DSS colitis.

Figure 4.3.2C: Histopathology in lung sections from isotype and anti-IL-6 treated DSS colitis.

Figure 4.3.3A: Proportion of myeloid cells in the lung of anti-IL-6 treated acute DSS colitis.

Figure 4.3.3B: Proportion of neutrophils and monocytes in the lung of acute DSS colitis

Figure 4.3.4A: Gene expression profile in the lung of anti-IL-6 treated acute DSS colitis.

Figure 4.3.4B: Gene expression profile in the lung of anti-IL-6 treated acute DSS colitis continued.

Figure 4.3.5A: TNF and IFN- γ protein levels in the lung of anti-IL-6 treated acute DSS colitis.

Figure 4.3.5B: CCL2 and IL-1 β protein levels in the lungs of anti-IL-6 treated DSS colitis.

Figure 4.3.6C: PAFR protein levels in the lung of anti-IL-6 treated acute DSS colitis.

Figure 4.3.7A: Proportion of neutrophils and monocytes in the blood of anti-IL-6 treated acute DSS colitis.

Figure 4.3.7B: Systemic IL-6 levels in anti-IL-6 treated acute DSS colitis mice.

Figure: 4.3.7C: The influence of IL-6 on the differentiation of myeloid progenitor cells and the proportion of mature neutrophils in the bone marrow of acute DSS colitis mice.

Chapter 5

Figure 5.2.1 Time course of PAFR antagonist (CV-6209) interventions in acute DSS colitis.

Figure 5.3.1A: Weight loss and colon shortening in CV-6209 treated DSS colitis.

Figure 5.3.1B: Histopathological scores from colon sections in CV-209 treated DSS colitis.

Figure 5.3.1C: Histopathology in colon sections from control and vehicle treated DSS colitis.

Figure 5.3.1D: Histopathology in colon sections from I.N. and I.V. CV-6209 treated DSS colitis.

Figure 5.3.1E: Cytokine signalling in the colon of CV-6209 treated DSS colitis.

Figure 5.3.2A: Histopathological scores from lung sections of CV-6209 treated DSS colitis.

Figure 5.3.2B: Histopathology in lung sections from control and vehicle treated DSS colitis.

Figure 5.3.2C: Histopathology in lung sections from I.N. and I.V CV-6209 treated DSS colitis.

Figure 5.3.3A: Proportion of myeloid cells in the lung of DSS colitis.

Figure 5.3.3B: Proportion of neutrophils and monocytes in the lung of DSS colitis.

Figure 5.3.4 Gene expression profile in the lung of CV-6209 treated DSS colitis.

Figure 5.3.5: CCL2 and IL1 β levels in the lung of CV-6209 treated DSS colitis.

Figure 5.3.6A: Proportion of neutrophils and monocytes in the blood of CV-6209 treated DSS colitis.

Figure 5.3.6B: Systemic IL-6 levels in CV-6209 treated DSS colitis.

Chapter 6

Figure 6.3.1A: PAFR expression is localised to leucocytes in the lungs of DSS colitis.

Figure 6.3.1B: PAFR positive leucocytes are increased in the lung of acute DSS colitis.

Figure 6.3.2A: Gene expression in RAW 264.7 macrophages exposed to serum from DSS colitis and treated with CV-6209.

Figure 6.3.2B: IL-1 β secreted by RAW 264.7 macrophages exposed to serum from DSS colitis treated with CV-6209.

Figure 6.3.3A: Bacterial load in the lungs of acute DSS colitis.

Figure 6.3.4A Gene expression in RAW 264.7 macrophage treated with LPS and CV-6209.

Figure 6.3.4B: IL-1 β secreted by RAW 264.7 macrophage treated with LPS and CV-6209.

Figure 6.3.5A Gene expression in RAW 264.7 macrophage treated with CCL2 and CV-6209.

Figure 6.3.5B: IL-1 β secreted by RAW 264.7 macrophage treated with CCL2 and CV-6209.

Figure 6.3.6: PAF secreted by RAW 264.7 macrophage treated with CCL2 and LPS in the presence of CV-6209.

Figure 6.3.7A: The ability of secretory factors from CCL2 and LPS treated RAW 267.4 macrophage to induce CD11b expression on neutrophils via PAFR signalling.

Figure 6.3.7B: The ability of secretory factors from CCL2 and LPS treated RAW 267.4 macrophage to induce superoxide production from neutrophils via PAFR signalling.

Appendices

Figure 8.1.1A: Lymphoid populations in the lungs of control mice.

Figure 8.1.1B: Lymphoid populations in the lungs of acute DSS colitis mice.

Figure 8.1.2A: Myeloid cell populations in the lungs of control mice.

Figure 8.1.2B: Myeloid cell populations in the lungs of acute DSS colitis mice.

Figure 8.1.3A: Myeloid cell populations in the blood of control mice.

Figure 8.1.3B: Myeloid cell populations in the blood of acute DSS colitis mice.

Figure 8.1.4A: Hematopoietic stem and progenitor cells in the bone marrow of control mice.

Figure 8.1.4B: Hematopoietic stem and progenitor cells in the bone marrow of DSS colitis mice

Figure 8.1.5A: Mature myeloid populations in the bone marrow of control mice.

Figure 8.1.5B: Mature myeloid populations in the bone marrow of DSS colitis mice.

Figure 8.2.1A: Myeloid cell populations in the lungs control mice.

Figure 8.2.1B: Myeloid cell populations in the lungs of naïve DSS colitis mice.

Figure 8.2.1C: Myeloid cell populations in the lungs of isotype treated DSS colitis mice.

Figure 8.2.1D: Myeloid cell populations in the lungs of anti-IL-6 treated DSS colitis mice.

Figure 8.2.2A: Myeloid cell populations in the blood of control mice.

Figure 8.2.2B: Myeloid cell populations in the blood of naïve DSS colitis mice.

Figure 8.2.2C: Myeloid cell populations in the blood of isotype treated DSS colitis mice.

Figure 8.2.2D: Myeloid cell populations in the blood of anti-IL-6 treated DSS colitis mice.

Figure 8.3.1A: Myeloid cell populations in the lungs of control mice.

Figure 8.3.1B: Myeloid cell populations in the lungs of vehicle treated DSS colitis mice.

Figure 8.3.1C: Myeloid cell populations in the lungs of I.N. CV-6209 treated DSS colitis mice.

Figure 8.3.1D: Myeloid cell populations in the lungs of I.V. CV-6209 treated DSS colitis mice.

Figure 8.3.2A: Myeloid cell populations in the blood of control mice.

Figure 8.3.2B: Myeloid cell populations in the blood of vehicle treated DSS colitis mice.

Figure 8.3.2C: Myeloid cell populations in the blood of I.N. CV-6209 treated DSS colitis mice.

Figure 8.3.2D: Myeloid cell populations in the blood of I.V. CV-6209 treated DSS colitis mice.

Figure 8.4: Gating strategy utilized for the quantification of bacterial load by FISH-FLOW.

Figure 8.5A: CD11b expression on neutrophils incubated with supernatants

from vehicle stimulated macrophages in the presence and absence of CV-6209

Figure 8.5B: CD11b expression on neutrophils incubated with supernatants from CCL2 stimulated macrophages in the presence and absence of CV-6209.

Figure 8.5C: Superoxide levels in neutrophils incubated with supernatants from vehicle stimulated macrophages in the presence and absence of CV-6209.

Figure 8.5D: Superoxide levels in neutrophils incubated with supernatants from CCL2 stimulated macrophages in the presence and absence of CV-6209.

Figure 8.5E: CD11b expression on neutrophils treated directly with LPS in the absence of CV-6209

List of tables

Chapter 1

Table 1.4 Overview of the IBD-induced respiratory pathologies.

Chapter 2

Table 2.5 Gastrointestinal histopathological scoring system for DSS colitis.

Table 2.6 Histopathological scoring system for mouse lungs.

Table 2.10: Staining panel and gating strategy for immunophenotyping mouse tissues by flow cytometry.

Table 2.16: Composition and vendor of reagents used in experiments.

List of equations

Equation 3.3.1: Method utilized to calculate weight loss due to colitis.

Abbreviations:

2,4,6-trinitrobenzenesulfonic acid (TNBS)

3-diaminobenzidine (DAB)

4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)

Alpha-1-antitrypsin (A1AT)

Bovine serum albumin (BSA)

Bronchial hyperresponsiveness (BHR)

Bronchoalveolar lavage (BAL)

Cadherin type-1 (CDH1)

Caspase recruitment domain-containing protein 15 (CARD15)

C-C chemokine receptor 2 (CCR2)

C-C chemokine receptor 9 (CCR9)

Centimetre of water (cmH₂O)

Central nervous system (CNS)

Chemokine (C-C) motif ligand 2 (CCL2)

Chronic obstructive pulmonary disease (COPD)

Ciliary neurotrophic factor (CNTF)

Colony forming units (CFU)

Crohn's disease (CD)

Cycle threshold (Ct)

Degrees Celsius ($^{\circ}\text{C}$)

Dextran sulfate sodium (DSS)

Diffusion capacity of the lung for carbon monoxide (DL_{co})

Dihydroethidium (DHE)

Dulbecco's modified eagle medium (DMEM)

Enzyme-linked immunosorbent assay (ELISA)

Ethylenediaminetetraacetic acid (EDTA)

Extracellular matrix protein-1 (ECM1)

Extraintestinal manifestations (EIM)

Forced expiratory flow (FEF)

Forced vital capacity (FVC)

Fraction of exhaled nitric oxide (FE_{No})

Gastrointestinal tract (GI)

Genome wide association studies (GWAS)

Glycoprotein 130 (Gp130)

Hanks buffered salt solution (HBSS)

Hematopoietic stem cells (HSC)

Hepatocyte nuclear factor-4 alpha (HNF4A)

High-resolution computer tomography (HRCT)

Horse radish peroxidase (HRP)

Human leucocyte antigen-B27 (HLA-B27)

Hypothalamic-pituitary adrenal (HPA)

Immunoglobulin G (IgG)

Inflammatory bowel diseases (IBD)

Interferon- γ (IFN- γ)

Interleukin IL-12 (IL-12)

Interleukin-1 beta (IL-1 β)

Interleukin-10 (IL-10)

Interleukin-11 (IL-11)

Interleukin-12B (IL-12B)

Interleukin-13 (IL-13)

Interleukin-17 (IL-17)

Interleukin-2 (IL-2)

Interleukin-22 (IL-22)

Interleukin-23 (IL-23)

Interleukin-23 receptor (IL-23R)

Interleukin-27 (IL-27)

Interleukin-4 (IL-4)

Interleukin-5 (IL-5)

Interleukin-6 (IL-6)

Interleukin-8 (IL-8)

Intraperitoneal (IP)

Janus kinase-2 (JAK2)

Laminin beta-1 (LAMB1)

Leukemia inhibitory factor (LIF)

Lipopolysaccharide (LPS)

Lipoteichoic acid (LTA)

Litre (L)

Major histocompatibility complex (MHC) class II

Matrix metalloproteases (MMP)

Mean linear intercept (L_M)

Medium-chain-fatty acids (MCFAs)

Membrane bound IL-6 receptor (IL-6R)

Mesenteric lymph nodes (MLN)

Microgram (μg)

Microlitre (μL)

Micrometre (μm)

Micromole (μM)

Millilitre (mL)

Millimole (mM)

Minutes (min)

Moloney murine leukemia virus reverse transcriptase (MMLV-RT)

Monocyte chemoattractant protein-1 (MCP-1)

Mucin 2 (MUC2)

Mucosal vascular addressin cell adhesion molecule 1(MAdCAM-1)

Multi-potent progenitor cells (MPP)

Muramyl dipeptide (MDP)

NACHT, LRR, and PYD domains-containing protein 3 (NALP3)

Nanogram (ng)

Natural killer cells (NK)

Nucleotide-binding oligomerization domain-containing protein 2 (NOD2)

Oncostatin M (OSM)

p38 mitogen-activated protein kinases pathway (p38 MAPK)

PAF acetylhydrolase (PAF-AH)

Paraformaldehyde (PFA)

Pattern recognition receptor (PRR)

Periodic acid–Schiff Alcian blue (PAS-AB)

Phosphate buffered saline (PBS)

Platelet activating factor (PAF)

Platelet activating factor receptor (PAFR).

Primary sclerosing cholangitis (PSC)

Potential hydrogen (pH)

Pulmonary parenchymal disease (PPD)

Quantitative polymerase chain reaction (qPCR)

Reactive oxygen species (ROS)

Revolutions per minute (RPM)

Ribonucleic acid (RNA)

Seconds (s)

Signal transducer and activator of transcription-3 (STAT3)

Soluble IL-6 receptor (sIL-6R)

T helper 1 (Th1)

T helper 17 (Th17)

T helper 2 (Th2)

T regulatory (Treg)

TBS (tris-buffered saline)

TBS-T (tris-buffered saline – 0.1% tween 20)

TBS-TX (tris-buffered saline – 0.1% triton X-100)

Toll-like receptor 2 (TLR2)

Toll-like receptor 4 (TLR4)

Toll-like receptors (TLR)

Transforming growth factor beta (TGF- β)

Tumor necrosis factor (TNF)

Ulcerative colitis (UC)

Vascular cell adhesion molecule 1 (VCAM1)